217 articles with NovoCure Ltd.
Novocure announced today that it will report financial results for the second quarter 2018 on Thursday, July 26, 2018, before the U.S. financial markets open.
Novocure to Present INNOVATE-3 Phase 3 Pivotal Trial Design in Recurrent Ovarian Cancer at the American Society of Clinical Oncology Annual Meeting 2018
INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer
Novocure announced changes to its board of directors. Dr. David T. Hung and Sherilyn D. McCoy, both experienced executive leaders, were elected to Novocure’s board at the annual general meeting of shareholders on May 31.
2,009 active patients at March 31, 2018, an increase of 59 percent versus March 31, 2017
Final STELLAR data exceeded the results of the interim analysis for all efficacy endpoints
NCCN Guidelines Recommend Optune in Combination with Temozolomide as a Category 1 Treatment for Newly Diagnosed Glioblastoma
Updated clinical practice guidelines indicate, based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate
Delivered record quarterly net revenues of $53.7 million, representing 77 percent growth versus December 31, 2016, and 7 percent growth versus September 30, 2017
The cash will be used to to execute core strategies of driving commercial adoption of Optune and advancing the clinical pipeline.
Novocure plans to discuss these results with investors at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco.
Novocure Release: JAMA Publishes Final Analysis of EF-14 Phase III Pivotal Trial of Optune Together With Temozolomide Demonstrating Unprecedented Survival Results for Newly Diagnosed Glioblastoma
Novacure announced today that the final analysis of its phase 3 pivotal trial of Optune in combination with temozolomide for the treatment of newly diagnosed glioblastoma (GBM) has been published in the Journal of the American Medical Association (JAMA).
Novocure Receives FDA IDE Approval for Its PANOVA 3 Phase III Pivotal Clinical Trial in Advanced ...
12/18/2017NovoCure announced today that it has received a FDA Investigational Device Exemption (IDE) approval to initiate its PANOVA 3 clinical trial.
Novocure Receives Reimbursement Approval for Optune in Japan for the Treatment of Newly Diagnosed Glioblastoma
Optune is a noninvasive, portable device approved in Japan to treat newly diagnosed and recurrent GBM.
Patients Who Used Optune More Than 90 Percent of the Time Had the Greatest Chance of Survival in Novocure's EF-14 Trial
This is a median survival of 24.9 months from randomization and a five-year survival of 29.3 percent.
Novocure Announces 10 Presentations on Simulation Studies Aiming to Optimize Treatment Delivery of Tumor Treating Fields at 22nd Annual Meeting of the Society for Neuro-Oncology
The 10 presentations include data on a new array layout that could allow delivery of TTFields to infra-tentorial brain tumors, and data showing correlation between TTFields intensity within and surrounding patients’ tumors and their clinical outcomes.
Novocure Announces 13 Preclinical Presentations Highlighting Data on Tumor Treating Fields’ Mechanism of Action at 22nd Annual Meeting of the Society for Neuro-Oncology
In total, 60 abstracts on Tumor Treating Fields, including two oral presentations, will be presented.
Novocure Announces Six Clinical Presentations on Novocure's Phase III Pivotal EF-14 Trial Data in Newly Diagnosed Glioblastoma at 22nd Annual Meeting of the Society for Neuro-Oncology
NovoCure announced today six clinical presentations on Novocure’s phase 3 pivotal EF-14 trial data in newly diagnosed glioblastoma (GBM) at the 22nd Annual Meeting of the Society for Neuro-Oncology (SNO), November 16 through November 19, in San Francisco
Novocure today reported financial results for the three and nine months ended September 30, 2017, highlighting year-over-year and sequential growth in active patients and net revenues.
NovoCure Release: Combination Of Optune With Temozolomide Demonstrates Unprecedented Five-Year Survival For Newly Diagnosed Glioblastoma Patients
NovoCure Announces Data Presentations At The American Society For Radiation Oncology’s 2017 Annual Meeting